-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Viridian Therapeutics, Inc.\DE annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from 2013 to 2024.
- Viridian Therapeutics, Inc.\DE Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $177M, a 2058% increase year-over-year.
- Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2024 was $458M, a 103% increase from 2023.
- Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2023 was $226M, a 30% decline from 2022.
- Viridian Therapeutics, Inc.\DE annual Net Cash Provided by (Used in) Financing Activities for 2022 was $322M, a 157% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)